Year: 2017

Ovarian Cancer Cells Manipulate Surrounding Normal Cells to Aid Tumor Growth

Tumors do not grow in isolation, but are surrounded by a rich microenvironment that contains blood vessels, fibroblasts, immune cells, and a multitude of other components. Cancer cells can influence their microenvironment through extracellular signaling mechanisms to enable and/or enhance

Multispectral Tumor Imaging May Guide Precision Immunotherapy

While novel immunotherapies are revolutionizing the way some cancers are treated, not all patients will respond to treatment, underlining the need for biomarkers that can predict potential clinical benefit and monitor a patient’s response. Until recently, immune activity within and

Combination Targeted Therapy Improves Survival of Stage III Melanoma Patients

It is estimated that 40% of melanomas contain BRAF mutations that promote cancer cell growth. While previous studies have shown that treatment with the combination of inhibitors targeting BRAF (dabrafenib) and MEK (trametinib) improved survival in patients with advanced, unresectable

Hillman Legacy Lives On at UPMC Hillman Cancer Center

Through Hillman Foundation and Henry L. Hillman Foundation, the late Henry and Elsie Hillman made generous contributions throughout the Pittsburgh region, especially in science and medicine. Their vision of making Pittsburgh a renowned leader in cancer care became a reality

Prestigious Federal Contract Supports Drug Pharmacology Studies at Hillman

Last August, UPMC Hillman Cancer Center became one of only two academic centers in the nation to secure a competitive contract from the National Cancer Institute (NCI) to perform preclinical and clinical pharmacology research critical to the development of new

Medicaid Cuts Linked to Later-Stage Cancer Diagnoses

Medicaid is the largest insurance program in the United States and provides health care coverage for many low-income individuals. Medicaid is administered at the state level, and therefore, the structure and extent of coverage provided in each state varies across

Targeting Regulatory T Cells Could Improve Cancer Immunotherapy

Immunotherapy drugs that utilize the immune system to detect and kill cancer cells have been successful against several cancers, yet they are still only effective in approximately 10 to 30 percent of patients with certain tumor types. UPMC Hillman Cancer

Novel Gene Editing Approach to Cancer Treatment Shows Promise in Mice

A novel gene therapy using CRISPR genome editing technology effectively targets cancer-causing “fusion genes” and improves survival in mouse models of aggressive liver and prostate cancers, UPCI researchers reported in a study published this month in Nature Biotechnology. Fusion genes,

New Study Demonstrates Synergistic Anti-Cancer Effects of Oncolytic Virus Combined with Immune Checkpoint Inhibitor

Oncolytic viruses can selectively kill cancer cells and cancer-promoting cells, either directly by binding and infecting them, or indirectly by eliciting a targeted immune response against them. UPCI investigators have been examining the anti-cancer efficacy of an immune-stimulating vaccinia virus,

Breast Cancer Patient-Led Advocate Group Awards UPCI Researcher with Leadership Grant

The Metastatic Breast Cancer Network is a volunteer, patient-led advocacy organization that seeks to address the unique needs and concerns of women and men who are living with metastatic or stage IV breast cancer. One of the ways in which

Top